Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.

Abstract

There is an increasing body of evidence demonstrating that growth factor networks are highly interactive with oestrogen receptor (ER) signalling in the control of breast cancer growth. As such, tumour responses to anti- hormones are likely to be a composite of the ER and growth factor inhibitory activity of these agents. The current article examines the modulation of growth factor networks during endocrine response, and presents in vitro and clinical evidence that epidermal growth factor receptor signalling, maintained in either an ER-dependent or -independent manner, is critical to anti- hormonal-resistant breast cancer cell growth. The considerable potential of the epidermal growth factor receptor-selective tyrosine kinase inhibitor, ZD 1839 (Iressa; AstraZeneca) to efficiently treat, and perhaps even prevent, endocrine-resistant breast cancer is highlighted.

0200400'02'04'06'08'10'12'14'16
Citations per Year

2,281 Citations

Semantic Scholar estimates that this publication has 2,281 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Nicholson2001ModulationOE, title={Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.}, author={Robert Ian Nicholson and I R Hutcheson and Maureen E. Harper and J M Knowlden and Denise Barrow and R A McClelland and H. E. Jones and Alan E. Wakeling and Julia M W Gee}, journal={Endocrine-related cancer}, year={2001}, volume={8 3}, pages={175-82} }